MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies. This collaboration combines MiLaboratories’ cutting-edge RNA kit technology for immune sequencing with Miltenyi Biotec’s robust production and commercialization capabilities.
Under this agreement, MiLaboratories will grant exclusive rights to its innovative RNA kits immune sequencing technology to Miltenyi Biotec. This technology has been instrumental in advancing research and development in the field of immunology and personalized medicine. Miltenyi Biotec will leverage its global reach and expertise in biotechnology to produce and commercialize these kits, making them widely available to researchers and clinicians worldwide.
A cornerstone of this partnership is the integration of MiLaboratories’ renowned software solutions, MiXCR and Platforma, into Miltenyi Biotec’s offerings. These software platforms are leaders in next-generation sequencing (NGS) data analysis, providing powerful, user-friendly tools for genomic data interpretation. Customers purchasing RNA kits from Miltenyi Biotec will now benefit from seamless access to MiXCR and Platforma, enhancing their research capabilities and efficiency.
Also Read: FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
“This partnership is a significant milestone in our mission to accelerate the development of next-generation therapies,” said Stan Poslavsky, CEO of MiLaboratories. “By combining our innovative RNA technologies and software platforms with Miltenyi Biotec’s manufacturing and commercial strengths, we are poised to make a substantial impact in the field of genomics and personalized medicine.”
Jürgen Schmitz, Managing Director at Miltenyi Biotec, added, “We are thrilled to partner with MiLaboratories, a company that shares our commitment to advancing human health. Their RNA kits technology for immune sequencing complements our molecular analysis product portfolio perfectly. Moreover, their software solutions will offer our customers unparalleled support in data analysis. Together, we are building the future for next-generation therapies.”
SOURCE: Businesswire